1996
DOI: 10.1111/j.1749-6632.1996.tb26392.x
|View full text |Cite
|
Sign up to set email alerts
|

Phase I Clinical and Pharmacological Studies of 20‐(S)‐Camptothecin and 20‐(S)‐9‐Nitrocamptothecin as Anticancer Agents

Abstract: Groups of 52 and 29 patients with refractory cancers received either native camptothecin (CPT) or 9-nitrocamptothecin (9NC), respectively, in Phase I clinical trials designed to determine the maximum tolerated dose, toxicity and potential efficacy of orally administered camptothecins. Favorable responses occurred with both compounds (11% after CPT, 24% after 9NC). Although both agents could be taken safely for extended periods, dose limiting toxicities were substantial. Diarrhea was the major clinical problem … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
37
1

Year Published

2001
2001
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 60 publications
(38 citation statements)
references
References 7 publications
0
37
1
Order By: Relevance
“…Toxicity and Tolerability. The toxicity profiles of schedules A and B were similar with diarrhea, nausea, neutropenia, and thrombocytopenia as the primary toxicities (7,17,18). A summary of toxicities for evaluable patients on schedule A during cycle 1 are included in Table 2.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Toxicity and Tolerability. The toxicity profiles of schedules A and B were similar with diarrhea, nausea, neutropenia, and thrombocytopenia as the primary toxicities (7,17,18). A summary of toxicities for evaluable patients on schedule A during cycle 1 are included in Table 2.…”
Section: Resultsmentioning
confidence: 99%
“…In Phase II and III studies, 9NC was administered orally daily ϫ 5 days/week for 8 weeks (one cycle); however, the optimal schedule of administration of camptothecin analogues, especially 9NC, is unclear (7,17,18). As a result, we performed the first study evaluating intermittent schedules of 9NC and have shown that intermittent schedules of 9NC are tolerable and may be active.…”
Section: Discussionmentioning
confidence: 99%
“…Diarrhoea is a well-known side effect of camptothecin and its derivatives. Oral administration of irinotecan (Soepenberg et al, 2002), 20-S-camptothecin (Natelson et al, 1996), 9-nitrocamptothecin (Verschraegen et al, 1998), topotecan (Creemers et al, 1997;Gerrits et al, 1998) and 9-AC (Mani et al, 1998;De Jonge et al, 1999) induced diarrhoea in 24 -54% of administered cycles. Prolonged oral administration (21 days) of topotecan resulted in severe diarrhoea in 22%, which could not be controlled with loperamide (Creemers et al, 1997).…”
Section: Discussionmentioning
confidence: 99%
“…The recommended Phase II dose was 1.5 mg/m 2 per day for patients with little or no prior therapy. 9 We therefore chose to study 9-NC in a 2-arm Phase II trial to define its activity and toxicity profiles. Patients with gastrointestinal leiomyosarcomas comprised one arm, and patients with other soft-tissue sarcomas were enrolled on the other arm to allow independent evaluation of response rates.…”
mentioning
confidence: 99%